6-K filed Jul 28, 2026 at 12:50 ET
GSK reported Q2 2026 core results with total sales of £8.4 billion (+5% CER) and core EPS of 50.5p (+9% CER), driven by strong Specialty Medicines and Vaccines growth. However, total operating profit plunged 75% to £481 million due to £1.9 billion in impairments, primarily from the failed camlipixant trial, and higher contingent consideration charges. The company reaffirmed 2026 guidance at the upper half of the 3-5% turnover growth range and announced a new 'Accelerate Growth' restructuring program targeting £1.9 billion in annual savings by 2029, alongside the recently closed $10.6 billion Nuvalent acquisition.